Date: 2012-02-01
Type of information: Private placement
Company: Wilex (Germany)
Investors:
Amount: € 9.93 million
Funding type: private placement
Planned used: Wilex AG plans to use the gross proceeds of approx. € 10 million from the rights issue to finance its ongoing clinical studies and further growth as well as to enhance its equity.
Others: * On February 1, 2012, Wilex has announced that its shareholders exercised their subscription and oversubscription rights for all of the 3,201,928 new no-par value bearer shares for € 3.10 per share by the end of the subscription period on 30 January 2012. As a result, the Executive Management Board has resolved with the approval of the Supervisory Board to set the total volume of the rights issue at 3,201,928 new shares.
Shareholders exercised subscription rights for a total of 2,417,077 new shares, which corresponds to a subscription ratio of more than 75%. The Company\'s main shareholders –dievini Hopp BioTech holding GmbH & Co. KG, Verwaltungsgesellschaft des Golf Club St. Leon-Rot mbH and UCB Pharma S.A. – exercised all of their subscription rights. Approximately 68 % of the oversubscription was assigned to shareholders within the free float.
* On January 9, 2012, the Executive Management Board of Wilex has resolved, with the approval of
the Supervisory Board, to increase the Company\'s share capital using authorised capital from € 21,613,035.00 by up to € 3,201,928.00 to up to € 24,814,963.00 by issuing up to 3,201,928 new no-par value bearer shares with a pro-rata interest in capital of € 1.00 each and full entitlement to dividends effective 1 December 2011 in return for cash contributions. Landesbank Baden-Württemberg, Stuttgart, Germany, will offer the new shares to shareholders at a 27:4 ratio by means of an indirect subscription right. Hence, shareholders will be entitled to subscribe for 4 new shares for each 27 existing shares held. One of the existing shareholders has undertaken to waive its subscription rights with respect to 21 shares in order to ensure an even subscription ratio.
The subscription period will begin on 17 January 2012 and is expected to end on 30 January 2012. The subscription price is fixed at € 3.10. There will be no organised trading in subscription rights.
The new shares are to be admitted to trading in the regulated market on Frankfurt stock exchange and in the Prime Standard (regulated market segment that imposes further postadmission obligations) on the Frankfurt stock exchange without the publication of an offering prospectus. The new WILEX shares are due to be listed on the Frankfurt stock exchange on 6 February 2012.
The main shareholders dievini Hopp BioTech holding GmbH & Co. KG, Verwaltungsgesellschaft des Golfclubs St. Leon-Rot GmbH and UCB Pharma S.A – whose current interest in the voting capital of Wilex total 58.7% – have advised that they intend to exercise at least their subscription rights.
Therapeutic area: Cancer - Oncology - Inflammatory diseases
